Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016
Posted on: Tuesday, 25 March 2008, 09:00 CDT
WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the obesity drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will experience more than five-fold growth, rising from $478 million in 2006 to more than $2.7 billion in 2016. The market will grow most rapidly in the United States, where sales will increase from $222 million in 2006 to nearly $2 billion in 2016.
The new Pharmacor report entitled Obesity finds that the significant market growth will be driven by a number of emerging therapies, including Arena Pharmaceuticals' lorcaserin and Amylin Pharmaceuticals' pramlintide/leptin combination, which are both expected to launch in the world's major pharmaceutical markets by 2011. Lorcaserin, pramlintide/leptin and other emerging novel therapies will capture 80% of the total obesity market in 2016 as physicians switch from the few currently available therapies to new treatments with novel mechanisms of action.
The report also finds that increasing concern of the Food and Drug Administration (FDA) regarding the long-term safety of drug treatments for chronic conditions such as obesity poses one of the most significant threats to companies developing anti-obesity drugs. For example, although Sanofi- Aventis's Acomplia (rimonabant) had been widely anticipated to become a key therapy for obesity, its blockbuster potential was eliminated after a negative opinion of the drug was issued by an FDA advisory panel last year. According to the report, similar safety concerns will plague Merck's taranabant and Pfizer's CP-945598, which belong to the same drug class as rimonabant.
"Given the high prevalence of obesity in the world's major pharmaceutical markets, the opportunity for agents that fulfill the need for safe, effective and well-tolerated weight-loss therapies is significant," said Donny Wong, Ph.D. principal analyst at Decision Resources. "Although the most efficacious emerging obesity drugs are combination therapies with multiple mechanisms of action, most of the late-stage therapies in development lack blockbuster potential because they are either associated with safety concerns or are available only in inconvenient injectable formulations."
About Obesity
The obesity epidemic is recognized as one of the most important public health challenges in the world. In 2006, the prevalent population of obese and overweight individuals in the world's major pharmaceutical markets surpassed 300 million. The U.S. Centers for Disease Control and Prevention predicts that obesity-related illnesses will soon overtake smoking-related illnesses as the leading cause of mortality in the United States. The rising cost of treating obesity-related illnesses such as type 2 diabetes and cardiovascular disease poses huge challenges to national healthcare systems worldwide.
About Decision Resources
Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Driven by Launch of Emerging Therapies, Overall Prostate Cancer Drug Market Will Increase by $2 Billion Through 2018
- Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer Drug Market to Nearly Triple to Almost $10 Billion in 2018
- Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
- Launch of Highly Anticipated Oral Agents and Increasing Use of Current and Emerging Injectable Drugs Will Drive the Multiple Sclerosis Drug Market to Nearly $10 Billion in 2018
- Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
- Examine the Obesity Drug Markets in the US and EU: Including Analysis of Product Pipelines and the Competitive Environment
- Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson's Disease Drug Market Over the Next Decade
- Emergence of Drugs From Elan/Wyeth, Eli Lilly, Myriad Genetics and Medivation Will Drive the Alzheimer's Disease Drug Market to Nearly Triple By 2017
- Increase in Diabetes and Obesity Numbers Driving Cardiovascular Drug Market Towards the $100 Billion Mark
- By 2020, the Population Aged 65 or Older in the United States is Projected to Reach 55 Million (16.3% of the Overall U.S. Population) a Good Demographic for the Geriatric Drug Market
 |
 |
User Comments (0)
RSS Feeds